miR221/222 in Cancer: Their Role in Tumor Progression and Response to Therapy

被引:381
作者
Garofalo, M. [4 ]
Quintavalle, C. [1 ,2 ]
Romano, G. [3 ]
Croce, C. M. [4 ]
Condorelli, G. [1 ,2 ]
机构
[1] Univ Naples Federico II, Dept Cellular & Mol Biol & Pathol, Biotechnol Sci Fac, I-80131 Naples, Italy
[2] CNR Naples, IEOS, Naples, Italy
[3] Fdn IRCCS SDN, Naples, Italy
[4] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA
关键词
Cancer; cancer therpay; microRNA; ESTROGEN-RECEPTOR-ALPHA; SQUAMOUS-CELL CARCINOMA; BREAST-CANCER; MICRORNA EXPRESSION; HEPATOCELLULAR-CARCINOMA; TAMOXIFEN RESISTANCE; MIR-222; EXPRESSION; GLIOBLASTOMA CELLS; TRAIL RESISTANCE; TISSUE INHIBITOR;
D O I
10.2174/156652412798376170
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
miRNAs are small non-coding RNAs of similar to 24 nt that can block mRNA translation and/or negatively regulate its stability. There is a large body of evidence that dysregulation of miRNAs is a hallmark of cancer. miRNAs are often aberrantly expressed and their function is linked to the regulation of oncogenes and/or tumor suppressor genes involved in cell signaling pathway. miR-221 and miR-222 are two highly homologous microRNAs, whose upregulation has been recently described in several types of human tumors. miR-221/222 have been considered to act as oncogenes or tumor suppressors, depending on tumor system. Silencing oncomiRs or gene therapy approaches, based on re-expression of miRNAs that are down- regulated in cancer cells, could represent a novel anti-tumor approach for integrated cancer therapy. Here we will review the role of miR-221/222 in cancer progression and their use as prognostic and therapeutic tools in cancer.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 54 条
[1]
Acunzo M., 2011, Oncogene
[2]
Ahonen M, 1998, CANCER RES, V58, P2310
[3]
Endocrine-responsive breast cancer and strategies for combating resistance [J].
Ali, S ;
Coombes, RC .
NATURE REVIEWS CANCER, 2002, 2 (02) :101-+
[4]
Estrogen receptors as therapeutic targets in breast cancer [J].
Ariazi, Eric A. ;
Ariazi, Jennifer L. ;
Cordera, Fernando ;
Jordan, V. Craig .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (03) :181-202
[5]
Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro - TIMP-3 promotes apoptosis [J].
Baker, AH ;
Zaltsman, AB ;
George, SJ ;
Newby, AC .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (06) :1478-1487
[6]
MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[7]
Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells [J].
Bhaumik, D. ;
Scott, G. K. ;
Schokrpur, S. ;
Patil, C. K. ;
Campisi, J. ;
Benz, C. C. .
ONCOGENE, 2008, 27 (42) :5643-5647
[8]
THE X-RAY CRYSTAL-STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN NEUTROPHIL COLLAGENASE INHIBITED BY A SUBSTRATE-ANALOG REVEALS THE ESSENTIALS FOR CATALYSIS AND SPECIFICITY [J].
BODE, W ;
REINEMER, P ;
HUBER, R ;
KLEINE, T ;
SCHNIERER, S ;
TSCHESCHE, H .
EMBO JOURNAL, 1994, 13 (06) :1263-1269
[9]
Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia [J].
Calin, GA ;
Dumitru, CD ;
Shimizu, M ;
Bichi, R ;
Zupo, S ;
Noch, E ;
Aldler, H ;
Rattan, S ;
Keating, M ;
Rai, K ;
Rassenti, L ;
Kipps, T ;
Negrini, M ;
Bullrich, F ;
Croce, CM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (24) :15524-15529
[10]
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias [J].
Calin, GA ;
Liu, CG ;
Sevignani, C ;
Ferracin, M ;
Felli, N ;
Dumitru, CD ;
Shimizu, M ;
Cimmino, A ;
Zupo, S ;
Dono, M ;
Dell'Aquila, ML ;
Alder, H ;
Rassenti, L ;
Kipps, TJ ;
Bullrich, F ;
Negrini, M ;
Croce, CM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (32) :11755-11760